Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

✉ Email this page to a colleague

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket	⤷ Start Trial	Date Filed	2017-06-30
Court	District Court, N.D. West Virginia	Date Terminated	2020-06-22
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	James P. Mazzone
Patents	6,509,376; 6,926,907; 7,320,999; 7,619,001; 7,803,840; 8,399,514; 8,759,393
Link to Docket	External link to docket

Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-30				External link to document
2017-06-30	1	Complaint	“the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017	External link to document
2017-06-30	142	Status Report	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Biogen International GmbH v. Mylan (No. 1:17-cv-00116): Litigation Summary, Claims at Issue, and Risk Analysis for US Generic/Patent-Orange-Book Strategy

Last updated: July 25, 2026

Biogen International GmbH sued Mylan Pharmaceuticals Inc. in the Northern District of West Virginia over alleged patent infringement tied to Mylan’s FDA submission for a Biogen product. Case No. 1:17-cv-00116 reached post-filing procedural milestones typical of Hatch-Waxman patent disputes and was litigated as a US patent infringement matter under the 35 U.S.C. § 271(e)(2) framework for ANDA-triggered infringement risk.

A complete, decision-grade litigation summary requires docket-resolved facts (asserted patents, claim construction outcomes, infringement findings, settlement or dismissal terms, and any appeal disposition). Those specific docket facts are not available in the provided input, so an accurate litigation summary cannot be produced without fabricating the record.